Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
Sponsor: Ottawa Hospital Research Institute
Summary
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Official title: A Randomized Pragmatic Trial Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (REaCT-OGF)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
242
Start Date
2023-04-17
Completion Date
2026-10
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
Granulocyte Colony-Stimulating Factor (G-CSF)
Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
Locations (3)
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Lakeridge Health
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada